March 15, 2012 — Devicor Medical Products Inc. announced that it signed a distribution agreement with Carbon Medical Technologies Inc. Under the agreement Devicor, parent company of Mammotome, will have exclusive rights to market a new beta-glucan tissue marker developed by Carbon Medical Technologies. Financial terms of the agreement were not disclosed.
The new marker will be used in breast biopsies to mark soft tissue at the diagnostic site. The unique design and proprietary material of the product allows for enhanced visibility in all imaging modalities.
"Doctors have told us that consistent and long-lasting visibility under ultrasound and other imaging modalities is important for the treatment of their patients. We believe this product provides that solution," says Tom Daulton, CEO of Devicor and Mammotome.
"We are pleased to partner with Devicor and believe that our work has resulted in a clinically important marker product," says Dean Klein, president and CEO of Carbon Medical Technologies.
Mammotome, the worldwide leader of biopsy site markers and vacuum-assisted biopsy devices, sells products in nearly 50 countries around the world. In addition to this new device, the Mammotome family of marker products, which is used in the diagnosis of breast disease, includes MammoMARK, CorMARK and MicroMARK II.
"Devicor is making tremendous progress toward our goal of building a global medical device business. Our agreement with Carbon Medical Technologies is another example of how our company is investing in innovative products that help clinicians more effectively diagnose and treat patients," says Daulton.
For more information: www.mammotome.com